AP2002002501A0 - Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. - Google Patents

Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.

Info

Publication number
AP2002002501A0
AP2002002501A0 APAP/P/2002/002501A AP2002002501A AP2002002501A0 AP 2002002501 A0 AP2002002501 A0 AP 2002002501A0 AP 2002002501 A AP2002002501 A AP 2002002501A AP 2002002501 A0 AP2002002501 A0 AP 2002002501A0
Authority
AP
ARIPO
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba analog
Prior art date
Application number
APAP/P/2002/002501A
Other languages
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2002002501A0 publication Critical patent/AP2002002501A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/2002/002501A 1999-10-07 2000-01-05 Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. AP2002002501A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
AP2002002501A0 true AP2002002501A0 (en) 2002-06-30

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002501A AP2002002501A0 (en) 1999-10-07 2000-01-05 Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.

Country Status (38)

Country Link
EP (2) EP1221950B1 (hu)
JP (2) JP2003510356A (hu)
KR (1) KR20020060192A (hu)
CN (1) CN1387434A (hu)
AP (1) AP2002002501A0 (hu)
AR (1) AR029646A1 (hu)
AT (1) ATE269072T1 (hu)
AU (2) AU7663300A (hu)
BG (1) BG106548A (hu)
BR (1) BR0014598A (hu)
CA (1) CA2385930A1 (hu)
CO (1) CO5280195A1 (hu)
CR (1) CR6614A (hu)
CZ (1) CZ20021116A3 (hu)
DE (1) DE60011650T2 (hu)
DK (1) DK1221950T3 (hu)
EA (1) EA004266B1 (hu)
EE (1) EE200200185A (hu)
ES (1) ES2220542T3 (hu)
GT (1) GT200000166A (hu)
HR (1) HRP20020286A2 (hu)
HU (1) HUP0203466A3 (hu)
IL (1) IL148965A0 (hu)
IS (1) IS6318A (hu)
MA (1) MA26826A1 (hu)
MX (1) MXPA02003484A (hu)
NO (1) NO20021625L (hu)
NZ (1) NZ517949A (hu)
OA (1) OA12063A (hu)
PA (1) PA8504301A1 (hu)
PE (1) PE20010708A1 (hu)
PL (1) PL357498A1 (hu)
PT (1) PT1221950E (hu)
SK (1) SK4542002A3 (hu)
TR (1) TR200200913T2 (hu)
UY (1) UY26376A1 (hu)
WO (2) WO2001024792A1 (hu)
ZA (1) ZA200202675B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
ES2536534T3 (es) 2010-07-30 2015-05-26 Toray Industries, Inc. Agente terapéutico o agente profiláctico para el dolor neuropático
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
EP0942734A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
ATE269072T1 (de) 2004-07-15
ZA200202675B (en) 2003-04-15
KR20020060192A (ko) 2002-07-16
EP1233766A1 (en) 2002-08-28
HUP0203466A2 (hu) 2003-02-28
IS6318A (is) 2002-03-21
HUP0203466A3 (en) 2005-03-29
UY26376A1 (es) 2000-12-29
EA004266B1 (ru) 2004-02-26
EP1221950B1 (en) 2004-06-16
NO20021625D0 (no) 2002-04-05
WO2001024792A1 (en) 2001-04-12
TR200200913T2 (tr) 2002-09-23
CR6614A (es) 2003-12-04
CO5280195A1 (es) 2003-05-30
BG106548A (en) 2002-12-29
EP1221950A1 (en) 2002-07-17
BR0014598A (pt) 2002-06-11
DE60011650D1 (de) 2004-07-22
SK4542002A3 (en) 2003-09-11
MXPA02003484A (es) 2004-09-10
MA26826A1 (fr) 2004-12-20
CN1387434A (zh) 2002-12-25
PA8504301A1 (es) 2002-08-26
WO2001024792A9 (en) 2002-09-06
EE200200185A (et) 2003-04-15
PT1221950E (pt) 2004-08-31
GT200000166A (es) 2002-03-30
EA200200303A1 (ru) 2002-08-29
CZ20021116A3 (cs) 2003-05-14
DK1221950T3 (da) 2004-09-20
JP2003510356A (ja) 2003-03-18
NZ517949A (en) 2003-08-29
AU7663300A (en) 2001-05-10
DE60011650T2 (de) 2005-07-14
WO2001024791A1 (en) 2001-04-12
HRP20020286A2 (en) 2003-08-31
ES2220542T3 (es) 2004-12-16
PL357498A1 (en) 2004-07-26
OA12063A (en) 2006-05-03
NO20021625L (no) 2002-04-05
PE20010708A1 (es) 2001-07-27
IL148965A0 (en) 2002-11-10
CA2385930A1 (en) 2001-04-12
AU1696201A (en) 2001-05-10
JP2003510355A (ja) 2003-03-18
AR029646A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
WO1999017755A3 (en) Medicaments
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2005102390A3 (en) Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
HK1041808A1 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
CA2386230A1 (en) Modulators of cytokine mediated signalling pathways and integrin .alpha.v.beta.3 receptor antagonists for combination therapy
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
GB9917290D0 (en) Pharmaceutical composition
DE69732492D1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia
DOP2000000076A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un análogo estructural de gaba. (synergistic combinations of a nki receptor antagonist and a gaba structural analog)